Mutations in G protein β subunits promote transformation and kinase inhibitor resistance

Akinori Yoda, Guillaume Adelmant, Jerome Tamburini, Bjoern Chapuy, Nobuaki Shindoh, Yuka Yoda, Oliver Weigert, Nadja Kopp, Shuo Chieh Wu, Sunhee S. Kim, Huiyun Liu, Trevor Tivey, Amanda L. Christie, Kutlu G. Elpek, Joseph Card, Kira Gritsman, Jason Gotlib, Michael W. Deininger, Hideki Makishima, Shannon J. Turley & 9 others Nathalie Javidi-Sharifi, Jaroslaw P. Maciejewski, Siddhartha Jaiswal, Benjamin L. Ebert, Scott J. Rodig, Jeffrey Tyner, Jarrod A. Marto, David M. Weinstock, Andrew A. Lane

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Activating mutations in genes encoding G protein α (Gα) subunits occur in 4-5% of all human cancers, but oncogenic alterations in Gβ subunits have not been defined. Here we demonstrate that recurrent mutations in the Gβ proteins GNB1 and GNB2 confer cytokine-independent growth and activate canonical G protein signaling. Multiple mutations in GNB1 affect the protein interface that binds Gα subunits as well as downstream effectors and disrupt Gα interactions with the Gβγ dimer. Different mutations in Gβ proteins clustered partly on the basis of lineage; for example, all 11 GNB1 K57 mutations were in myeloid neoplasms, and seven of eight GNB1 I80 mutations were in B cell neoplasms. Expression of patient-derived GNB1 variants in Cdkn2a-deficient mouse bone marrow followed by transplantation resulted in either myeloid or B cell malignancies. In vivo treatment with the dual PI3K-mTOR inhibitor BEZ235 suppressed GNB1-induced signaling and markedly increased survival. In several human tumors, mutations in the gene encoding GNB1 co-occurred with oncogenic kinase alterations, including the BCR-ABL fusion protein, the V617F substitution in JAK2 and the V600K substitution in BRAF. Coexpression of patient-derived GNB1 variants with these mutant kinases resulted in inhibitor resistance in each context. Thus, GNB1 and GNB2 alterations confer transformed and resistance phenotypes across a range of human tumors and may be targetable with inhibitors of G protein signaling.

Original languageEnglish (US)
Pages (from-to)71-75
Number of pages5
JournalNature Medicine
Volume21
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Protein Subunits
GTP-Binding Proteins
Phosphotransferases
Mutation
Gene encoding
Neoplasms
Tumors
Substitution reactions
Cells
B-Lymphocytes
Phosphatidylinositol 3-Kinases
Dimers
Bone
Proteins
Fusion reactions
Myeloid Cells
Bone Marrow Transplantation
Cytokines
Genes
Phenotype

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Yoda, A., Adelmant, G., Tamburini, J., Chapuy, B., Shindoh, N., Yoda, Y., ... Lane, A. A. (2015). Mutations in G protein β subunits promote transformation and kinase inhibitor resistance. Nature Medicine, 21(1), 71-75. https://doi.org/10.1038/nm.3751

Mutations in G protein β subunits promote transformation and kinase inhibitor resistance. / Yoda, Akinori; Adelmant, Guillaume; Tamburini, Jerome; Chapuy, Bjoern; Shindoh, Nobuaki; Yoda, Yuka; Weigert, Oliver; Kopp, Nadja; Wu, Shuo Chieh; Kim, Sunhee S.; Liu, Huiyun; Tivey, Trevor; Christie, Amanda L.; Elpek, Kutlu G.; Card, Joseph; Gritsman, Kira; Gotlib, Jason; Deininger, Michael W.; Makishima, Hideki; Turley, Shannon J.; Javidi-Sharifi, Nathalie; Maciejewski, Jaroslaw P.; Jaiswal, Siddhartha; Ebert, Benjamin L.; Rodig, Scott J.; Tyner, Jeffrey; Marto, Jarrod A.; Weinstock, David M.; Lane, Andrew A.

In: Nature Medicine, Vol. 21, No. 1, 01.01.2015, p. 71-75.

Research output: Contribution to journalArticle

Yoda, A, Adelmant, G, Tamburini, J, Chapuy, B, Shindoh, N, Yoda, Y, Weigert, O, Kopp, N, Wu, SC, Kim, SS, Liu, H, Tivey, T, Christie, AL, Elpek, KG, Card, J, Gritsman, K, Gotlib, J, Deininger, MW, Makishima, H, Turley, SJ, Javidi-Sharifi, N, Maciejewski, JP, Jaiswal, S, Ebert, BL, Rodig, SJ, Tyner, J, Marto, JA, Weinstock, DM & Lane, AA 2015, 'Mutations in G protein β subunits promote transformation and kinase inhibitor resistance', Nature Medicine, vol. 21, no. 1, pp. 71-75. https://doi.org/10.1038/nm.3751
Yoda A, Adelmant G, Tamburini J, Chapuy B, Shindoh N, Yoda Y et al. Mutations in G protein β subunits promote transformation and kinase inhibitor resistance. Nature Medicine. 2015 Jan 1;21(1):71-75. https://doi.org/10.1038/nm.3751
Yoda, Akinori ; Adelmant, Guillaume ; Tamburini, Jerome ; Chapuy, Bjoern ; Shindoh, Nobuaki ; Yoda, Yuka ; Weigert, Oliver ; Kopp, Nadja ; Wu, Shuo Chieh ; Kim, Sunhee S. ; Liu, Huiyun ; Tivey, Trevor ; Christie, Amanda L. ; Elpek, Kutlu G. ; Card, Joseph ; Gritsman, Kira ; Gotlib, Jason ; Deininger, Michael W. ; Makishima, Hideki ; Turley, Shannon J. ; Javidi-Sharifi, Nathalie ; Maciejewski, Jaroslaw P. ; Jaiswal, Siddhartha ; Ebert, Benjamin L. ; Rodig, Scott J. ; Tyner, Jeffrey ; Marto, Jarrod A. ; Weinstock, David M. ; Lane, Andrew A. / Mutations in G protein β subunits promote transformation and kinase inhibitor resistance. In: Nature Medicine. 2015 ; Vol. 21, No. 1. pp. 71-75.
@article{f7924d8a81ca42488fd7fd50c8acce38,
title = "Mutations in G protein β subunits promote transformation and kinase inhibitor resistance",
abstract = "Activating mutations in genes encoding G protein α (Gα) subunits occur in 4-5{\%} of all human cancers, but oncogenic alterations in Gβ subunits have not been defined. Here we demonstrate that recurrent mutations in the Gβ proteins GNB1 and GNB2 confer cytokine-independent growth and activate canonical G protein signaling. Multiple mutations in GNB1 affect the protein interface that binds Gα subunits as well as downstream effectors and disrupt Gα interactions with the Gβγ dimer. Different mutations in Gβ proteins clustered partly on the basis of lineage; for example, all 11 GNB1 K57 mutations were in myeloid neoplasms, and seven of eight GNB1 I80 mutations were in B cell neoplasms. Expression of patient-derived GNB1 variants in Cdkn2a-deficient mouse bone marrow followed by transplantation resulted in either myeloid or B cell malignancies. In vivo treatment with the dual PI3K-mTOR inhibitor BEZ235 suppressed GNB1-induced signaling and markedly increased survival. In several human tumors, mutations in the gene encoding GNB1 co-occurred with oncogenic kinase alterations, including the BCR-ABL fusion protein, the V617F substitution in JAK2 and the V600K substitution in BRAF. Coexpression of patient-derived GNB1 variants with these mutant kinases resulted in inhibitor resistance in each context. Thus, GNB1 and GNB2 alterations confer transformed and resistance phenotypes across a range of human tumors and may be targetable with inhibitors of G protein signaling.",
author = "Akinori Yoda and Guillaume Adelmant and Jerome Tamburini and Bjoern Chapuy and Nobuaki Shindoh and Yuka Yoda and Oliver Weigert and Nadja Kopp and Wu, {Shuo Chieh} and Kim, {Sunhee S.} and Huiyun Liu and Trevor Tivey and Christie, {Amanda L.} and Elpek, {Kutlu G.} and Joseph Card and Kira Gritsman and Jason Gotlib and Deininger, {Michael W.} and Hideki Makishima and Turley, {Shannon J.} and Nathalie Javidi-Sharifi and Maciejewski, {Jaroslaw P.} and Siddhartha Jaiswal and Ebert, {Benjamin L.} and Rodig, {Scott J.} and Jeffrey Tyner and Marto, {Jarrod A.} and Weinstock, {David M.} and Lane, {Andrew A.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1038/nm.3751",
language = "English (US)",
volume = "21",
pages = "71--75",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Mutations in G protein β subunits promote transformation and kinase inhibitor resistance

AU - Yoda, Akinori

AU - Adelmant, Guillaume

AU - Tamburini, Jerome

AU - Chapuy, Bjoern

AU - Shindoh, Nobuaki

AU - Yoda, Yuka

AU - Weigert, Oliver

AU - Kopp, Nadja

AU - Wu, Shuo Chieh

AU - Kim, Sunhee S.

AU - Liu, Huiyun

AU - Tivey, Trevor

AU - Christie, Amanda L.

AU - Elpek, Kutlu G.

AU - Card, Joseph

AU - Gritsman, Kira

AU - Gotlib, Jason

AU - Deininger, Michael W.

AU - Makishima, Hideki

AU - Turley, Shannon J.

AU - Javidi-Sharifi, Nathalie

AU - Maciejewski, Jaroslaw P.

AU - Jaiswal, Siddhartha

AU - Ebert, Benjamin L.

AU - Rodig, Scott J.

AU - Tyner, Jeffrey

AU - Marto, Jarrod A.

AU - Weinstock, David M.

AU - Lane, Andrew A.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Activating mutations in genes encoding G protein α (Gα) subunits occur in 4-5% of all human cancers, but oncogenic alterations in Gβ subunits have not been defined. Here we demonstrate that recurrent mutations in the Gβ proteins GNB1 and GNB2 confer cytokine-independent growth and activate canonical G protein signaling. Multiple mutations in GNB1 affect the protein interface that binds Gα subunits as well as downstream effectors and disrupt Gα interactions with the Gβγ dimer. Different mutations in Gβ proteins clustered partly on the basis of lineage; for example, all 11 GNB1 K57 mutations were in myeloid neoplasms, and seven of eight GNB1 I80 mutations were in B cell neoplasms. Expression of patient-derived GNB1 variants in Cdkn2a-deficient mouse bone marrow followed by transplantation resulted in either myeloid or B cell malignancies. In vivo treatment with the dual PI3K-mTOR inhibitor BEZ235 suppressed GNB1-induced signaling and markedly increased survival. In several human tumors, mutations in the gene encoding GNB1 co-occurred with oncogenic kinase alterations, including the BCR-ABL fusion protein, the V617F substitution in JAK2 and the V600K substitution in BRAF. Coexpression of patient-derived GNB1 variants with these mutant kinases resulted in inhibitor resistance in each context. Thus, GNB1 and GNB2 alterations confer transformed and resistance phenotypes across a range of human tumors and may be targetable with inhibitors of G protein signaling.

AB - Activating mutations in genes encoding G protein α (Gα) subunits occur in 4-5% of all human cancers, but oncogenic alterations in Gβ subunits have not been defined. Here we demonstrate that recurrent mutations in the Gβ proteins GNB1 and GNB2 confer cytokine-independent growth and activate canonical G protein signaling. Multiple mutations in GNB1 affect the protein interface that binds Gα subunits as well as downstream effectors and disrupt Gα interactions with the Gβγ dimer. Different mutations in Gβ proteins clustered partly on the basis of lineage; for example, all 11 GNB1 K57 mutations were in myeloid neoplasms, and seven of eight GNB1 I80 mutations were in B cell neoplasms. Expression of patient-derived GNB1 variants in Cdkn2a-deficient mouse bone marrow followed by transplantation resulted in either myeloid or B cell malignancies. In vivo treatment with the dual PI3K-mTOR inhibitor BEZ235 suppressed GNB1-induced signaling and markedly increased survival. In several human tumors, mutations in the gene encoding GNB1 co-occurred with oncogenic kinase alterations, including the BCR-ABL fusion protein, the V617F substitution in JAK2 and the V600K substitution in BRAF. Coexpression of patient-derived GNB1 variants with these mutant kinases resulted in inhibitor resistance in each context. Thus, GNB1 and GNB2 alterations confer transformed and resistance phenotypes across a range of human tumors and may be targetable with inhibitors of G protein signaling.

UR - http://www.scopus.com/inward/record.url?scp=84923075128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923075128&partnerID=8YFLogxK

U2 - 10.1038/nm.3751

DO - 10.1038/nm.3751

M3 - Article

VL - 21

SP - 71

EP - 75

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 1

ER -